HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: A meta-analysis

17Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Background and Aim: Human epidermal growth factor receptor (HER) family plays an important role in gastric cancer (GC), especially HER2. Too much attention has been paid to HER2; however, the functions of HER3 and HER4 overexpression in GC are always ignored. The clinicopathological and prognostic roles of HER3 and HER4 in GC are controversial. In this study, a systematic review and meta-analysis was conducted to evaluate the use of HER3 or HER4 as a predictor of clinicopathology and survival time in GC patients. Methods: Eligible studies were searched on PubMed, Ovid, Web of Science, and Cochrane databases through multiple search strategies. Data collection and statistical analysis were carried out by the Revman 5.3 software. The Newcastle-Ottawa scale was used to assess the quality of included studies. Results: A total of 448 studies about HER3 overexpression and GC, and 398 studies about HER4 overexpression and GC were searched. Of these, 5 eligible studies about HER3 including 1016 GC patients and 3 eligible studies about HER4 including 793 GC patients met the inclusion criteria. The results showed that HER3 and HER4 overexpression were significantly associated with depth of tumor invasion (OR = 0.44, 95%CI 0.29-0.67, P = 0.0002 and OR = 0.50, 95%CI 0.38-0.86, P = 0.007) and lymph node metastasis (OR = 0.40, 95% CI 0.20-0.77, P = 0.007 and OR = 0.57, 95%CI 0.38-0.86, P = 0.007), and HER3 overexpression reveals a tendency of later tumor node metastases (TNM) stage (OR = 0.50, 95% CI 0.22-1.15, P = 0.10) and predicts a worse survival time (RR = 0.71, 95%CI 0.61-0.84, P<0.00001), while HER4 overexpression had no correlation with TNM stage (OR = 0.60, 95%CI 0.20-1.78) and survival time (RR = 1.09, 95%CI 0.91-1.30). Conclusions: This meta-analysis indicated that HER3 plays an essential role in the clinicopathology and prognosis of GC. However, HER4 may not be an ideal prognostic factor for GC.

References Powered by Scopus

Meta-analysis in clinical trials

32714Citations
N/AReaders
Get full text

Statistical aspects of the analysis of data from retrospective studies of disease

13771Citations
N/AReaders
Get full text

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

13207Citations
N/AReaders
Get full text

Cited by Powered by Scopus

<sup>89</sup>Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors

58Citations
N/AReaders
Get full text

The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein

36Citations
N/AReaders
Get full text

Polymorphisms in RAS/RAF/MEK/ERK pathway are associated with gastric cancer

30Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cao, G. D., Chen, K., Xiong, M. M., & Chen, B. (2016). HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: A meta-analysis. PLoS ONE, 11(8). https://doi.org/10.1371/journal.pone.0161219

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

55%

Researcher 6

30%

Professor / Associate Prof. 2

10%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

57%

Biochemistry, Genetics and Molecular Bi... 6

26%

Agricultural and Biological Sciences 3

13%

Environmental Science 1

4%

Save time finding and organizing research with Mendeley

Sign up for free